Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.5150
+0.0150 (3.00%)
Oct 9, 2026, 11:38 AM HKT
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 2.08 billion as of October 9, 2026. It is the 19,235th most valuable company in the world and the 858th biggest in Hong Kong. Its market cap has decreased by 24.63% in one year.
Market Cap
2.08B
Enterprise Value
2.33B
Revenue
888.77M
Global Rank
Country Rank
#858 Hong Kong
PE Ratio
22.67
ChartMarket Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 2.08B, a decrease of -58.26%. That is a compound annual growth rate of -11.19%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 2.08B | 1.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Jiangsu Recbio Technology | 2.72B |
| HJ Science | 2.59B |
| Clover Biopharmaceuticals | 2.32B |
| Frontage Holdings | 2.25B |
| AIM Vaccine | 2.20B |
| Antengene Corporation | 2.19B |
| HighTide Therapeutics | 1.96B |
| Shandong Boan Biotechnology | 1.93B |